At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
QNCX Quince Therapeutics, Inc.
Market Closed 02-14 16:00:00 EST
1.40
-0.02
-1.41%
盘后1.35
-0.05-3.57%
19:59 EST
High1.48
Low1.38
Vol43.58K
Open1.42
D1 Closing1.42
Amplitude7.20%
Mkt Cap61.60M
Tradable Cap49.47M
Total Shares44.00M
T/O61.32K
T/O Rate0.12%
Tradable Shares35.34M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia
Quince Therapeutics, Inc., a preclinical stage biopharmaceutical company, develops precision therapeutics for debilitating and rare diseases. Its lead compound is NOV004, a systemically administered bone anabolic peptide engineered to target and concentrate at bone fracture sites. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.